KNP-501
/ Kanaph Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 10, 2023
Kanaph Therapeutics’ EGFR inhibitor shows efficacy in models of EGFR mutation-driven cancers
(Bioworld)
- "Researchers from Kanaph Therapeutics Inc. have reported the discovery and preclinical evaluation of a small-molecule EGFR inhibitor, KNP-501, being developed as an anticancer agent."
Preclinical
1 to 1
Of
1
Go to page
1